Company Overview and News


Add ENDP
to your dashboard

Headline News

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-6)

Endo on the Street: Analyst Recommendations in November

2017-11-17 marketrealist
Headquartered in Dublin, Ireland, Endo International (ENDP) is a generics and specialty branded pharmaceutical company whose subsidiaries include Endo Health Solutions, Paladin Labs, and Par Pharmaceutical Holdings. (22-0)

Recro Pharmaceuticals: Prescriptions For Pain Are A Prescription For Gain

2017-11-16 seekingalpha
Recro is severely undervalued due to the negative cash flows of one segment masking company value. (47-0)

Antares Pharma On Sale

2017-11-14 seekingalpha
Antares stock had dropped 61% from a recent high after the company received notification from the FDA that it would not approve Xyosted in October. (186-3)

Endo International plc 2017 Q3 - Results - Earnings Call Slides

2017-11-13 seekingalpha
The following slide deck was published by Endo International plc in conjunction with their 2017 Q3 earnings call. (22-1)

Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

2017-11-10 zacks
Endo International plc (ENDP - Free Report) reported third-quarter 2017 results wherein both earnings and revenues surpassed estimates. Earnings from continuing operations were 91 cents which beat the Zacks Consensus Estimate of 70 cents. However, earnings declined 10% from the year-ago quarter. (56-1)

BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

2017-11-10 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) reported a loss of 21 cents per share in the third quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 22 cents and the year-ago loss of 30 cents. (30-1)

Endo International Plc (ENDP) Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day ladies and gentlemen, and welcome to the Endo International Third Quarter 2017 Earnings Conference Call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Steve Mock, Senior Vice President of Investor Relations and Corporate Affairs. Sir, you may begin. (22-1)

Endo International Plc to Host Earnings Call

2017-11-09 accesswire
(22-0)

CORRECTED-Kentucky accuses Endo of contributing to opioid epidemic

2017-11-07 reuters
Nov 6 (Reuters) - Kentucky accused units of Endo International Plc on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic. (22-0)

BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

2017-11-07 zacks
BioDelivery Sciences International, Inc. (BDSI - Free Report) is scheduled to report third-quarter 2017 results on Nov 9 after market close. Last quarter, the company delivered a negative earnings surprise of 8%. (87-0)

Kentucky Is Latest State to Sue an Opioid-Painkiller Maker - WSJ

2017-11-07 wsj
Kentucky became the latest state to sue an opioid-painkiller maker, but unlike the others it is focusing its lawsuit solely on subsidiaries of Endo International PLC, maker of a drug recently pulled from the market over abuse concerns. (22-0)

Kentucky accuses Endo of contributing to opioid epidemic

2017-11-06 channelnewsasia
REUTERS: Kentucky accused units of Endo International Plc on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic. (22-0)

Kentucky accuses Endo of contributing to opioid epidemic

2017-11-06 reuters
(Reuters) - Kentucky accused units of Endo International Plc on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic. (22-0)

Teva Pharmaceutical Could Settle At $10

2017-11-06 seekingalpha
Before reading on, know that coverage on Teva Pharmaceutical (TEVA) has been met with little success. The stock did not bottom since first making that call in February and again in August. The latest quarterly earnings report pushed the stock lower. The market assigned an even steeper discount on its shares as uncertainties from generic drug competition, debt management, and falling cash flow weigh on its stock price. (187-0)

CUSIP: G30401956